ArticleBMC primary care2026
Mean platelet volume and the risk of diabetic nephropathy in type 2 diabetes: a retrospective Cohort study.
Article in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus is a global health concern, and diabetic nephropathy (DN) is a serious complication associated with increased morbidity and mortality. Early identification of at-risk individuals may enable timely intervention. This study aimed to evaluate whether mean platelet volume (MPV) serves as a marker for DN and to identify associated risk factors.
methodsIn this retrospective cohort study using routinely collected clinical data, patients with type 2 diabetes aged ≥ 20 years who attended the Primary Care Unit of Songklanagarind Hospital between 2013 and 2017 were followed until 2023. Medical records were reviewed for anthropometric, clinical, and laboratory data, including MPV and urine albumin-to-creatinine ratio (UACR). DN was defined as UACR > 30 mg/g on ≥ 2 of 3 measurements within 6 months or estimated glomerular filtration rate < 60 mL/min/1.73 m² for > 3 months. Of 681 records screened, 450 patients were included after excluding those with prior DN, incomplete key data, or insufficient follow-up assessments, which may introduce selection bias. Cox regression analysis was used to identify factors associated with DN.
resultsAmong 450 participants (mean age 61.3 ± 10.4 years; 58.2% female), unadjusted baseline comparisons showed that those who developed DN had higher baseline weight and serum creatinine. Over 2,373 person-years (median follow-up 5.21 years), 36 incident cases occurred (cumulative incidence 8%; incidence rate 15.1 per 1,000 person-years). In the multivariate time-dependent Cox model, male sex was significantly associated with an increased risk of DN (HR, 2.39; 95% CI, 1.21–4.72). MPV showed a strong association with DN (HR, 25.81; 95% CI, 1.54–433.79), with evidence of attenuation over time (interaction HR, 0.46; 95% CI, 0.21–1.01). Age and hypertension were not significantly associated with the outcome.
conclusionsMale sex and higher MPV were independently associated with incident DN in this cohort, with MPV demonstrating a time-dependent effect characterized by attenuation over time. These findings suggest that higher MPV may be associated with early risk; however, its predictive performance was modest, and its clinical utility for risk stratification remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.